Clinical Trial

Impact of Dapagliflozin in Anemic Chronic Kidney Disease Patients

Recruiting Phase 2
View on ClinicalTrials.gov →
Record status
This record was last updated April 2, 2025 (before its estimated October 2025 completion). Its status may not reflect the trial's current state.
Summary
Dapagliflozin is a sodium-glucose co-transporter 2 (SGLT2) inhibitor, primarily used in the management of type 2 diabetes mellitus. Emerging research suggests that SGLT2 inhibitors may offer additional benefits, including reducing the risk of cardiovascular events and renal complications. Post hoc analyses of previous clinical trials have shown that patients treated with SGLT2 inhibitors exhibited higher levels of hemoglobin and hematocrit compared to those in the control group. These findings suggest that dapagliflozin's ability to elevate hemoglobin levels could potentially be utilized for the treatment of anemia in patients with chronic kidney disease.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2025-03-20.
Status change: Not Yet Recruiting → Recruiting 2025-03-27
Trial Details
NCT Number NCT06897605
Lead Sponsor Mansoura University
Conditions Chronic Kidney Disease(CKD), Anemia, Kidney Disease, Chronic
Enrollment 80 participants
Start Date 2025-04-01
Primary Completion 2025-10 (estimated)
Study Completion 2025-10 (estimated)
Updated on ClinicalTrials.gov 2025-04-02